View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2016	Feb. 15, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	0001607962
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		16,351,009
Entity Public Float			$ 59,417,492
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS $ in Thousands	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
CURRENT ASSETS:
Cash and cash equivalents	$ 23,678	$ 17,869
Trade receivable, net	1,254	2,146
Prepaid expenses and other current assets	1,291	1,227
Inventories	3,264	2,534
Total current assets	29,487	23,776
LONG-TERM ASSETS
Other long term assets	1,018	470
Property and equipment, net	1,258	1,328
Total long-term assets	2,276	1,798
Total assets	31,763	25,574
CURRENT LIABILITIES:
Current maturities of long term loan	7,495	0
Trade payables	3,424	2,474
Employees and payroll accruals	1,019	1,221
Deferred revenues and customers advances	54	199
Other current liabilities	406	449
Total current liabilities	12,398	4,343
LONG-TERM LIABILITIES
Long term loan, net of current maturities	10,518	0
Deferred revenues	284	171
Other long-term liabilities	303	140
Total long-term liabilities	11,105	311
Total liabilities	23,503	4,654
COMMITMENTS AND CONTINGENT LIABILITIES
Share capital
Ordinary share of NIS 0.01 par value-Authorized: 250,000,000 shares at December 31, 2016 and 2015; Issued and outstanding: 16,338,257 and 12,222,583 shares at December 31, 2016 and 2015, respectively	45	33
Additional paid-in capital	114,707	94,876
Accumulated deficit	(106,492)	(73,989)
Total shareholders’ equity	8,260	20,920
Total liabilities and shareholders’ equity	$ 31,763	$ 25,574

CONSOLIDATED BALANCE SHEETS (Parenthetical) - ₪ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Ordinary shares, par value (in USD per share)	₪ 0.01	₪ 0.01
Ordinary shares, shares authorized (in shares)	250,000,000	250,000,000
Ordinary shares, shares Issued (in shares)	16,338,257	12,222,583
Ordinary shares, shares outstanding (in shares)	16,338,257	12,222,583

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	$ 5,869	$ 3,746	$ 3,951
Cost of revenues	5,133	3,532	4,106
Expense related to settlement of BIRD Foundation grants (see Note 7c)	0	0	466
Gross profit (loss)	736	214	(621)
Operating expenses:
Research and development, net	9,028	5,937	8,563
Sales and marketing	13,961	13,056	7,389
General and administration	8,188	6,395	3,352
Total operating expenses	31,177	25,388	19,304
Operating loss	(30,441)	(25,174)	(19,925)
Financial expenses, net	2,059	188	1,698
Loss before income taxes	(32,500)	(25,362)	(21,623)
Income taxes	3	53	45
Net loss	$ (32,503)	$ (25,415)	$ (21,668)
Net loss per ordinary share, basic and diluted (in USD per share)	$ (2.47)	$ (2.10)	$ (6.34)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted (in shares)	13,178,107	12,115,038	3,766,694

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
$ in Thousands

USD ($)

Series C convertible preferred shares

USD ($)

Series D convertible preferred shares

USD ($)

Series E convertible preferred shares

USD ($)

Convertible Preferred Shares

USD ($)

Convertible Preferred Shares

Series C convertible preferred shares

Convertible Preferred Shares

Series D convertible preferred shares

Convertible Preferred Shares

Series E convertible preferred shares

Ordinary Share

USD ($)

series

Additional paid-in capital

USD ($)

Additional paid-in capital

Series C convertible preferred shares

USD ($)

Additional paid-in capital

Series D convertible preferred shares

USD ($)

Additional paid-in capital

Series E convertible preferred shares

USD ($)

Accumulated deficit

USD ($)

IPO

USD ($)

IPO

Ordinary Share

USD ($)

IPO

Additional paid-in capital

USD ($)

ATM Offering Program

USD ($)

ATM Offering Program

Ordinary Share

USD ($)

^[1],[2]

ATM Offering Program

Additional paid-in capital

USD ($)

Follow-On Public Offering

USD ($)

Follow-On Public Offering

Ordinary Share

USD ($)

Follow-On Public Offering

Additional paid-in capital

USD ($)

Balance at Dec. 31, 2013

$ 5,631

$ 32,537

$ (26,906)

Balance (in shares) at Dec. 31, 2013 | shares

^[1]

327,403

185,688

^[2]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Exercise of warrants into convertible preferred shares

$ 3,825

$ 57

$ 3,825

$ 57

Exercise of warrants into convertible preferred shares (in shares) | shares

^[1]

17,705

263

Issuance of convertible preferred shares

$ 1,114

$ 7,895

$ 1,114

$ 7,895

Issuance of convertible preferred shares (in shares) | shares

^[1]

4,131

75,695

Conversion of convertible preferred shares into ordinary shares

$ 22

^[1],[2]

(22)

Conversion of convertible preferred shares into ordinary shares (in shares) | shares

^[1]

(425,197)

7,838,640

^[2]

Issuance of warrants

5,555

Issuance of ordinary shares

$ 36,263

$ 9

^[1],[2]

$ 36,254

Issuance of ordinary shares (in shares) | shares

^[1],[2]

3,450,000

Exercise of warrants into ordinary shares (in shares) | shares

^[1],[2]

157,618

Share-based compensation to employees and non employees

5,179

Issuance of ordinary share upon exercise of stock options by employees

$ 1

^[1],[2]

Issuance of ordinary share upon exercise of stock options by employees (in shares) | shares

^[1],[2]

346,608

Net loss

(21,668)

Balance at Dec. 31, 2014

43,853

$ 0

^[1]

$ 32

^[1],[2]

92,395

(48,574)

Balance (in shares) at Dec. 31, 2014 | shares

^[1]

11,978,554

^[2]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Exercise of warrants into ordinary shares (in shares) | shares

^[1],[2]

49,684

Share-based compensation to employees and non employees

2,345

Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees

137

$ 1

^[1],[2]

136

Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees (in shares) | shares

^[1],[2]

194,345

Net loss

(25,415)

Balance at Dec. 31, 2015

20,920

$ 0

^[1]

$ 33

^[1],[2]

94,876

(73,989)

Balance (in shares) at Dec. 31, 2015 | shares

^[1]

12,222,583

^[2]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Issuance of warrants

^[3]

1,239

Issuance of ordinary shares

^[4]

$ 4,099

$ 2

$ 4,097

$ 11,089

$ 9

^[1],[2]

$ 11,080

Issuance of ordinary shares (in shares) | shares

^[1],[2],[4]

692,062

3,250,000

Exercise of warrants into ordinary shares (in shares) | shares

^[1],[2]

45,116

Share-based compensation to employees and non employees

3,398

Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees

$ 1

^[1],[2]

Issuance of ordinary share upon exercise of stock options and RSUs by employees and non employees (in shares) | shares

^[1],[2]

128,496

Net loss

(32,503)

Balance at Dec. 31, 2016

$ 8,260

$ 0

^[1]

$ 45

^[1],[2]

$ 114,707

$ (106,492)

Balance (in shares) at Dec. 31, 2016 | shares

^[1]

16,338,257

^[2]

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Number of series of equity securities | series

[1]	All shares amount have been restated to reflect an 18-for-1 share split split as of August 26, 2014, see Note 8b.
[2]	The ordinary shares consist of two series, see note 8a.
[3]	See note 6.
[4]	See note 8c.

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2014
Convertible Preferred Shares \| Series E convertible preferred shares
Issuance cost		$ 212
IPO \| Ordinary Share
Issuance cost		$ 5,138
ATM Offering Program \| Ordinary Share
Issuance cost	$ 468
Follow-On Public Offering \| Ordinary Share
Issuance cost	$ 1,099

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (32,503)	$ (25,415)	$ (21,668)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	696	438	111
Share-based compensation to employees and non employees	3,398	2,345	5,179
Deferred taxes	(5)	(61)	(60)
Financial expenses related to convertible loans	675	0	0
Capital Gain	(8)	0	0
Revaluation of fair value of warrants to purchase convertible preferred share	0	0	(776)
Issuance of Warrants to venture lending	0	0	835
Issuance of Warrants to service provider	0	0	73
Financial expenses resulted from Issuance of Series D preferred shares to related party	0	0	1,114
Changes in assets and liabilities:
Trade receivables, net	892	(191)	(1,651)
Prepaid expenses and other current assets	(607)	(613)	(440)
Inventories	(911)	(2,525)	196
Trade payables	950	1,084	445
Employees and payroll accruals	(202)	349	308
Deferred revenues and advances from customers	(32)	121	(72)
Other liabilities	120	(712)	1,105
Severance pay, net	0	0	(18)
Net cash used in operating activities	(27,537)	(25,180)	(15,319)
Cash flows from investing activities:
Investment in short-term deposits	0	0	(10,000)
Maturities of short-term deposits	0	1,667	8,333
Purchase of property and equipment	(452)	(584)	(169)
Proceeds from sale of property and equipment	15	0	0
Net cash provided by (used in) investing activities	(437)	1,083	(1,836)
Cash flows from financing activities:
Proceeds from long term loan	20,000	0	0
Debt issuance cost	(501)	0	0
Repayment of long term loan	(922)	0	0
Issuance of ordinary shares in at-the-market offering, net of issuance expenses paid in the amount of $468	4,099	0	0
Issuance of ordinary shares and warrants in follow-on offering, net of issuance expenses in an amount of $1,099	11,089	0	0
Issuance of ordinary share upon exercise of stock options by employees and non employees	18	137	2
Issuance of Series E convertible preferred shares, including warrants, net	0	0	12,781
Exercise of warrants into Series C and D to convertible preferred shares	0	0	1,078
Issuance of ordinary shares in IPO, net of issuance expenses in an amount of $5,138	0	0	36,263
Net cash provided by financing activities	33,783	137	50,124
Increase (decrease) in cash and cash equivalents	5,809	(23,960)	32,969
Cash and cash equivalents at beginning of period	17,869	41,829	8,860
Cash and cash equivalents at end of period	23,678	17,869	41,829
Supplemental disclosures of non-cash flow information
Classification of inventory to property and equipment, net	181	768	0
Exercise of warrants to purchase preferred shares into Series C and D preferred shares	0	0	2,804
Reclassification of liability warrants to equity warrants	0	0	5,555
Supplemental disclosures of cash flow information:
Cash paid for income taxes	45	163	0
Cash paid for interest	$ 1,301	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2014 USD ($)
IPO
Issuance expenses	$ 5,138

GENERAL

12 Months Ended

Dec. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL


a.	ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date.


b.	RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) (formerly Argo Medical Technologies GmbH) incorporated under the laws of Germany on January 14, 2013.

The Company is designing, developing and commercializing the ReWalk system, an innovative exoskeleton that allow wheelchair-bound persons with mobility impairments or other medical conditions to stand and walk once again. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides valuable exercise and therapy. It also enables individuals to evaluate their capacity for using ReWalk Personal system in the future.

The Company markets and sells its products directly to institutions and individuals and through third-party distributors. The Company sells its products directly primarily in Germany and the United States, and primarily through distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States and Canada. RRG sell the Company’s products mainly in Germany and Europe.

During the fiscal year ended December 31, 2016, the Company issued and sold 692,062 ordinary shares at an average price of $6.60 per share under its ATM Offering Program. The gross proceeds to the Company were $4.6 million, and the net aggregate proceeds after deducting commissions, fees and offering expenses in the amount of $468 thousand were $4.1 million. The Company could raise up to $25 million under its ATM Offering Program. See Note 8c(1) below for more information about the Company’s ATM Offering Program.

In November 2016, the Company completed its follow-on public offering in which the Company issued and sold 3,250,000 units each consisting of one ordinary share and 0.75 of a warrant to purchase one ordinary share. Each unit was sold to the public at a price of $3.75 per unit. The total gross proceeds received from the follow-on public offering, before deducting commissions, discounts and expenses, were $12.2 million. See Note 8c(2) below for more information about the Company’s follow-on public offering.


g.	The Company depends on one contract manufacturer, Sanmina. Reliance on this vendor makes the Company vulnerable to possible capacity constraints and reduced control over component availability, delivery schedules, manufacturing yields and costs. This vendor accounted for 12% and 24% of the Company's total trade payables as of December 31, 2016 and 2015, respectively.

The Company has an accumulated deficit in the total amount of $106.5 million as of December 31, 2016 and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due.

The Company intends to finance operating costs over the next twelve months with existing cash on hand, reducing operating spend, issuances under the Company's ATM Offering Program, or other future issuances of equity and debt securities, or through a combination of the foregoing. See note 13a for further information about the Company's plan to reduce operating expenses.

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.

The consolidated financial statements for the year ended December 31, 2016 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

The consolidated financial statements are prepared according to United States generally accepted accounting principles (“U.S. GAAP”), applied on a consistent basis, as follows:


a.	Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates, judgments and assumptions. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company’s management evaluates estimates, including those related to inventories, fair values of share-based awards and warrants, contingent liabilities, provision for warranty, allowance for doubtful account and sales return reserve. Such estimates are based on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.


b.	Financial Statements in U.S. Dollars:

Most of the revenues and costs of the Company are denominated in United States dollars (“dollars”). Some of the Company’s and its subsidiaries’ revenues and costs are incurred in Euros and New Israeli Shekels (“NIS”), however, the selling prices are linked to the Company’s price list which is determined in dollars, the budget is managed in dollars, financing activities including loans and cash investments, are made in U.S. dollars and the Company’s management believes that the dollar is the primary currency of the economic environment in which the Company and each of its subsidiaries operate. Thus, the dollar is the Company’s and its subsidiaries’ functional and reporting currency.

Accordingly, transactions denominated in currencies other than the functional currency are re-measured to the functional currency in accordance with Accounting Standards Codification (“ASC”) No. 830, “Foreign Currency Matters” at the exchange rate at the date of the transaction or the average exchange rate in the relevant reporting period. At the end of each reporting period, financial assets and liabilities are re-measured to the functional currency using exchange rates in effect at the balance sheet date. Non-financial assets and liabilities are re-measured at historical exchange rates. Gains and losses related to re-measurement are recorded as financial income (expense) in the consolidated statements of operations as appropriate.


c.	Principles of Consolidation:

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, RRI and RRG. All intercompany transactions and balances have been eliminated upon consolidation.


d.	Cash Equivalents:

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.


e.	Inventories:

Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.

The Company periodically evaluates the quantities on hand relative to historical, current and projected sales volume. Based on this evaluation, an impairment charge is recorded when required to write-down inventory to its market value.

Cost is determined as follows:

Raw materials, auxiliary materials and spare parts - on the basis of raw materials cost on “first in, first out” basis.

Finished products - on the basis of raw materials and manufacturing costs on an average basis.

The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors, including historical usage rates and forecasted sales according to outstanding backlogs. Purchasing requirements and alternative usage are explored within these processes to mitigate inventory exposure. When recorded, the reserves are intended to reduce the carrying value of inventory to its net realizable value. In the years ended December 31, 2016, 2015 and 2014, the Company wrote off inventory in the amount of $237 thousand, $127 thousand and $76 thousand, respectively. If actual demand for the Company’s products deteriorates, or market conditions are less favorable than those projected, additional inventory reserves may be required.


f.	Related party:

The Company has a substantial shareholder named Yaskawa Electric Corporation (“YEC”).

In September 2013 the Company entered into a share purchase agreement and a strategic alliance with YEC, pursuant to which YEC has agreed to distribute the Company’s products, in addition to providing sales, marketing, service and training functions, in Japan, China (including Hong-Kong and Macau), Taiwan, South Korea, Singapore and Thailand.

As of December 31, 2016 and 2015 related party receivable were 24.2% and 11.3%, of trade receivable, net, respectively. Revenues from YEC during the years ended December 31, 2016, 2015 and 2014 amounted to $295 thousand, $246 thousand and $394 thousand respectively.


g.	Property and Equipment:

Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:



	%
Computer equipment	20-33 (mainly 33)
Office furniture and equipment	6 - 10 (mainly 10)
Machinery and laboratory equipment	15
Field service units	50
Leasehold improvements	Over the shorter of the lease term or estimated useful life


h.	Impairment of Long-Lived Assets:

The Company’s long-lived assets are reviewed for impairment in accordance with ASC No. 360, “Property, Plant and Equipment” whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December 31, 2016, 2015 and 2014, no impairment losses have been recorded.


i.	Other long term assets:

Other long term assets include long-term prepaid expenses and deposits for offices and cars leasing.


j.	Revenue Recognition:

The Company and its subsidiaries generate revenues from sales of products. The Company and its subsidiaries sell their products through a direct sales force and through distributors.

Revenues are recognized in accordance with ASC No. 605, “Revenue Recognition” (“ASC 605”), when delivery has occurred, persuasive evidence of an agreement exists, the fee is fixed and determinable, collectability is reasonably assured and no further obligations exist. Provisions are made at the time of revenue recognition for any applicable warranty cost expected to be incurred.

The timing for revenue recognition amongst the various products and customers is dependent upon satisfaction of such criteria and generally varies from either shipment or delivery to the customer depending on the specific shipping terms of a given transaction, as stipulated in the agreement with each customer.

Other than pricing terms which may differ due to the different volumes of purchases between distributors and end-users, there are no material differences in the terms and arrangements involving direct and indirect customers.

The Company’s products sold through agreements with distributors are non-exchangeable, non-refundable, non-returnable and without any rights of price protection or share rotation. Accordingly, the Company considers all the distributors to be end-users.

The Company generally does not grant a right of return for its products. There have been a few occasions in which the Company experienced a return of its products. Therefore, the Company records reductions to revenue for expected future product returns based on the Company’s historical experience.

For systems sold to rehabilitation facilities the Company includes training and considers the elements in the arrangement to be a single unit of accounting. In accordance with ASC 605, the Company has concluded that the training is essential to the functionality of the Company’s systems. Therefore the Company recognizes revenue for the system and training only after delivery in accordance with the agreement delivery terms to the customer and after the training has been completed, once all other revenue recognition criteria have been met.

For sales of Personal systems to end users, and for sales of Personal or Rehabilitation systems to third party distributors, the Company does not provide training to the end user as this training is completed by the Rehabilitation centers or by the distributor that have previously completed the ReWalk Training program. Therefore the Company recognizes revenue in such sales upon delivery, assuming the other conditions for revenue recognition have been met.

In certain cases, when product arrangements are bundled with extended warranty, the separation of the extended warranty falls under the scope of ASC 605-20-25-1 through 25-6, and the separately price of the extended warranty stated in the agreement is deferred and recognized ratably over the extended warranty period.

Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues. The Company also offers a rent-to-purchase option of its ReWalk Personal device. Those transactions provide potential customers the option to lease the device for a short term, after which they can choose whether to purchase it. In such cases the Company recognize revenues over the period of the rent once all other revenue criteria are met.


k	Accounting for Share-Based Compensation:

The Company accounts for share-based compensation in accordance with ASC No. 718, “Compensation-Stock Compensation” (“ASC No. 718”). ASC No. 718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model (“OPM”). The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s consolidated statements of operations.

The Company recognizes compensation expenses for the value of its awards granted based on the straight-line method over the requisite service period of each of the awards, net of estimated forfeitures. ASC No. 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Estimated forfeitures are based on actual historical pre-vesting forfeitures.

The Company selected the Black-Scholes-Merton option pricing model as the most appropriate fair value method for its share-option awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary share, expected share price volatility and the expected option term. Expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The simplified method will continue to apply until enough historical experience is available to provide a reasonable estimate of the expected term. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

The fair value of the ordinary shares underlying the share options has historically been determined by the Company’s board of directors. As prior to the Company’s IPO, there had been no public market for the Company’s ordinary shares, the board of directors determined fair value of the ordinary shares at the time of grant of the option by considering a number of objective and subjective factors including data from other comparable companies, sales of ordinary shares and convertible preferred share to unrelated third parties, operating and financial performance, the lack of liquidity of capital share and general and industry specific economic outlook, among other factors.

Since the distributions and participation rights to security holders are different in a sale/liquidation scenario versus an IPO, the valuation of the Company was performed using a weighted average of the values derived from the following scenarios: 1) discounted cash flow (DCF) model, and the OPM method was then employed to allocate the enterprise value amongst the Company’s various equity classes, deriving a fully marketable value per share for the ordinary share; 2) IPO scenario; and 3) Implied value approach. Before the per share value was determined, a discount for lack of marketability and a voting right differential was applied, as applicable, to the ordinary shares and the founders shares.

Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded.

The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company's ordinary shares on the date of grant.

The fair value for options granted in 2016, 2015 and 2014 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions:



	December 31,
	2016	2015	2014
Expected volatility	53%-60%	60%	60%-70%
Risk-free rate	1.16%-1.60%	1.60%-1.95%	1.74%-1.95%
Dividend yield	—%	—%	—%
Expected term (in years)	5.31 - 6.11	5.73 - 6.11	5.81 - 6.11
Share price	$6.80 - $11.88	$7.30 - $20.97	$1.49 - $20.77

The Company accounts for options granted to consultants and other service providers under ASC No. 718 and ASC No. 505, “Equity-based payments to non-employees.” The fair value of these options was estimated using a Black-Scholes-Merton option-pricing model. In 2016, 2015 and 2014 the non-cash compensation expenses related to nonemployees were immaterial.

The non-cash compensation expenses related to employees and non employees for the years ended December 31, 2016, 2015 and 2014 amounted to $3,398 thousand, $2,345 thousand and $5,179 thousand respectively.


l.	Research and Development Costs:

Research and development costs are charged to the consolidated statement of operations as incurred and are presented net of the amount of any grants we receive for research and development in the period in which we receive the grant.


m.	Income Taxes

The Company accounts for income taxes in accordance with ASC No. 740, “Income Taxes” (“ASC No. 740”), using the liability method whereby deferred tax assets and liability account balances are determined based on the differences between financial reporting and the tax basis for assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to the amounts that are more likely-than-not to be realized.

ASC No. 740 contains a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes. The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The Company accrues interest and penalties related to unrecognized tax benefits in its taxes on income.


n.	Warranty:

The Company provides a two-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair.



	US Dollars in thousands
Balance at December 31, 2015	$	502
Provision	400
Usage	(404		)
Balance at December 31, 2016	$	498


o.	Concentrations of Credit Risks:

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.

The Company’s cash and cash equivalents are deposited in major banks in Israel, the United States and Germany. Such deposits in the United States may be in excess of insured limits and are not insured in other jurisdictions. The Company maintains cash and cash equivalents with diverse financial institutions and monitors the amount of credit exposure to each financial institution.

Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. one customer represented 0% and 21% of the Company's trade receivable, net balance as of December 31, 2016 and December 31, 2015, respectively

The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of December 31, 2016 and 2015 trade receivables are presented net of $333 thousand and $144 thousand allowance for doubtful accounts and net of sales return reserve of $105 thousand and $0, respectively.


p.	Accrued Severance Pay:

Pursuant to Israel’s Severance Pay Law, Israeli employees are entitled to severance pay equal to one month’s salary for each year of employment, or a portion thereof. All of the employees of the RRL elected to be included under section 14 of the Severance Pay Law, 1963 (“section 14”). According to this section, these employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.

Total Company expenses related to severance pay amounted to $226 thousand, $202 thousand and $170 thousand for the years ended December 31, 2016, 2015 and 2014, respectively.


q.	Fair Value Measurements:

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs when determining fair value. If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The three-tiers are defined as follows:


•	Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;


•	Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and


•	Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.


r.	Basic and Diluted Net Loss Per Share:

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.

Diluted net loss per share is computed by giving effect to all potential shares of ordinary shares, including stock options, convertible preferred share warrants, to the extent dilutive, all in accordance with ASC No. 260, “Earning Per Share”.

The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data):



	Year ended December 31
	2016			2015			2014
Net loss	$	(32,503	)	$	(25,415	)	$	(21,668	)
Convertible preferred shares dividend	—			—			(2,229		)

Net loss attributable to ordinary shares	(32,503		)	(25,415		)	(23,897		)
Shares used in computing net loss per ordinary shares, basic and diluted	13,178,107			12,115,038			3,766,694

Net loss per ordinary share, basic and diluted	$	(2.47	)	$	(2.10	)	$	(6.34	)

Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential shares of ordinary shares outstanding would have been anti-dilutive.


s.	Contingent liabilities

The Company accounts for its contingent liabilities in accordance with ASC No. 450, “Contingencies”. A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter.

See note 7e for further information.


t.	Government grants

Government grants received by the Company relating to categories of operating expenditures are credited to the consolidated statements of operations during the period in which the expenditure to which they relate is charged. Royalty and non-royalty-bearing grants from the Israel Innovation Authority, or the IIA, (formerly known as the Israeli Office of the Chief Scientist), from the Israel-U.S. Binational Industrial Research and Development Foundation (“BIRD”) and from the Israeli Fund for Promoting Overseas Marketing for funding certain approved research and development projects and sales and marketing activities are recognized at the time when the Company is entitled to such grants, on the basis of the related costs incurred, and are included as a deduction from research and development or sales and marketing expenses (see Note 7c).

The Company recorded royalty-bearing grants in the amount of $0, $214 and $76 for the years ended December 31, 2016, 2015 and 2014, respectively, as part of the research and development expenses.

The Company recorded royalty expenses in the amount of $0, $0 and $204 for the years ended December 31, 2016, 2015 and 2014, respectively, as part of the cost of revenues.


u.	New Accounting Pronouncements


i.	Revenues:

In 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In 2016, the FASB issued four amendments to ASU 2014-09. The standard is effective for public companies for annual and interim periods beginning after December 15, 2017. Early adoption is permitted as of one year prior to the current effective date. The guidance permits two implementation approaches, one requiring retrospective application of the new standard with restatement of prior years and one requiring prospective application of the new standard with disclosure of results under old standards. The Company has not selected an implementation approach. The Company elected not to adopt the standard early and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures.

ii. Going concern:

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.” ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods ending after December 15, 2016, with early adoption permitted. The Company adopted ASU 2014-15 for the year ended December 31, 2016 and updated the going concern disclosure accordingly.


ii.	Inventory:

In July 2015, the FASB issued ASU 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory," which changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 eliminates the guidance that entities consider replacement cost or net realizable value less an approximately normal profit margin in the subsequent measurement of inventory when cost is determined on a first-in, first-out or average cost basis. The provisions of ASU 2015-11 are effective for public entities with fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The adoption of this guidance by the Company is not expected to have a material impact on the Company's consolidated financial statements.


iii.	Leases:

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). Under the new guidance, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current generally accepted accounting principles, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification as a finance or operating lease. This ASU requires additional disclosures. The standard is effective for annual periods beginning after December 15, 2018 and interim periods within those fiscal years. The ASU requires adoption based upon a modified retrospective transition approach. Early adoption is permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on the Company's consolidated financial statements and related disclosures.


iv.	Share Based Compensation:

In March 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-09, Compensation-Stock Compensation (Topic 718). The new guidance simplifies several aspects of the accounting for share-based payment transactions, including forfeitures which can take effect when they occur, the income tax consequences, classification of awards, as either equity or liabilities, and classification on the statement of cash flows. The standard also requires that shares withheld to satisfy tax withholding obligations associated with the vesting of restricted stock awarded to employees to be presented as a financing activity in the statement of cash flows. The amendments in this standard are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early adoption is permitted. The Company adopted this ASU effective January 1, 2017 and have elected to change our accounting policy regarding forfeitures. Previously, we estimated forfeitures expected to occur in the determination of compensation costs. Going forward we will recognize forfeitures in the period they occur. The Company does not expect the adoption to have a material impact on the Company's consolidated financial statements.


v.	Cash Flow:

In August 2016, the FASB issued ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments.” The standard addresses several matters of diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows including the presentation of debt extinguishment costs and distributions received from equity method investments. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods and allows for retrospective adoption with early adoption permitted. The Company has not yet determined whether it will elect early adoption and is currently evaluating the impact of the pending adoption of this ASU on its consolidated financial statements and related disclosures.

On November 17, 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force).” This ASU requires the statement of cash flows to explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents are to be included with cash and cash equivalents when reconciling the beginning of period and end of period amounts shown on the statement of cash flows. ASU No. 2016-18 will be effective for us as of January 1, 2018. The Company is currently reviewing the effect of this ASU to the Company's financial statements.

PREPAID EXPENSES AND OTHER CURRENT ASSETS

12 Months Ended

Dec. 31, 2016

Prepaid Expense and Other Assets, Current [Abstract]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

The components of prepaid expenses and other current assets are as follows (in thousands):



	December 31,
	2016		2015
Government institutions	$	113	$	209
Prepaid expenses	355		316
Deposit	—		43
Deferred tax	152		147
Other assets	671		512

	$	1,291	$	1,227

INVENTORIES

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

INVENTORIES

The components of inventory are as follows (in thousands):



	December 31,
	2016		2015
Raw materials	$	—	$	450
Finished products	3,264		2,084

	$	3,264	$	2,534

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT, NET

The components of property and equipment, net are as follows (in thousands):



	December 31,
	2016		2015
Cost:
Computer equipment	$	709	$	656
Office furniture and equipment	293		286
Machinery and laboratory equipment	573		471
Field service units	771		575
Leasehold improvements	358		113

	2,704		2,101



	December 31,
	2016		2015
Accumulated depreciation	1,446		773

Property and equipment, net	$	1,258	$	1,328

Depreciation expenses amounted to $696 thousand, $438 thousand and $111 thousand for the years ended December 31, 2016, 2015 and 2014, respectively.

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES

On December 30, 2015, the Company entered into the Loan Agreement with Kreos pursuant to which Kreos extended a line of credit to us in the amount of $20.0 million. On January 4, 2016, the Company drew down $12.0 million under the Loan Agreement. Under the terms of the Loan Agreement the Company were entitled to draw down up to an additional $8.0 million until December 31, 2016, if the Company raised $10.0 million or more in the issuance of shares of our capital stock (including debt convertible into shares of its capital stock) by December 31, 2016. On December 28, 2016, the Company drew down the remaining $8.0 million available under the Loan Agreement. Pursuant to the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests.

The Loan has a maturity of 36 months and bears annual interest of 10.75%, which is to be paid monthly. The principal of the Loan is to be paid in 24 monthly payments, beginning in January 2017, except for the last loan payment, which was paid in advance on the Draw Down Date (as defined below). The repayment period will be extended to 36 months if the Company raises $20.0 million or more in connection with the issuance of shares of its capital stock (including debt securities convertible into shares of the Company’s capital stock) prior to the expiration of the respective initial 24-month period.

On January 4, 2016 (the “Draw Down Date”), the Company drew down $12.0 million, net of $415 thousand in loan transaction fees and and $660 thousand as advance payment. Additional loan transaction fees in the amount of $26 thousand were paid after the Draw Down Date. Out of the $441 thousand in total loan transaction fees, $140 thousand were deferred until December 28, 2016 when the Company drew down the remaining $8.0 million available under the Loan Agreement. Total fees paid during the fiscal year ended December 31, 2016, in connection with the Loan Agreement amounted to $501 thousand.

Repayment of the Loan and payment of all other amounts owed to Kreos are to be made in U.S. dollars.

The Company recorded interest expense in the amount of $2 million during the fiscal year ended December 31, 2016.

In connection with the Loan Agreement, on December 30, 2015, the Company also granted Kreos a warrant to purchase 119,295 ordinary shares of the Company at an exercise price of $9.64 per share. In connection with the $8.0 million drawdown under the Loan Agreement on December 28, 2016, the Company has granted additional warrants of 47,717. The total number of warrants represents the right to purchase167,012 ordinary shares. The increase was based on the terms of the warrant, which provide that the amount of the warrant will be increased by 5.75% of any additional drawdowns. The Kreos warrant is exercisable, in whole or in part, at any time prior to the earliest of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of the Company with or into, or the sale or license of all or substantially all the assets or shares of the Company to, any other entity or person, other than a wholly-owned subsidiary of the Company, excluding any transaction in which shareholders of the Company prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.

On December 30, 2015 and December 28, 2016, the Company calculated the value of its freestanding warrant to purchase its ordinary shares in the amount of $1.2 million (net of $42 thousand issuance expenses) and $78 thousand (net of $2 thousand issuance expenses), respectively, by using the relative fair value method and utilizing an option pricing method. The Company has recorded the value of the Kreos Warrant, together with the Loan's issuance costs, as debt discount which is being accreted as interest expense using the effective-interest method over the remaining term of the Loan.

The following assumptions were used to estimate the value of the Kreos warrant on December 28, 2016 and December 30, 2015:



	December 28, 2016		December 30, 2015
Expected volatility	53	%	60	%
Risk-free rate	2.51	%	2.52	%
Dividend yield	—	%	—	%
Expected term (in years)	9		10

COMMITMENTS AND CONTINGENT LIABILITIES

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENT LIABILITIES


a.	Purchase commitment:

The Company has contractual obligations to purchase goods from its contract manufacturer. Purchase obligations do not include contracts that may be canceled without penalty. As of December 31, 2016, non-cancelable outstanding obligations amounted to approximately $2.2 million.


b.	Lease commitment: the Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2017 and 2025.

The future minimum lease commitments of the Company and its subsidiaries under various non-cancelable operating lease agreements in respect of premises, that are in effect as of December 31, 2016, are as follows:



2017	495
2018	547
2019	558
2020	567
2021 and Thereafter	2,219
Total	$	4,386

Total rent expenses for the years ended December 31, 2016, 2015 and 2014 were $650 thousand, $260 thousand and $168 thousand, respectively.

RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in 2017-2019.

RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $53 thousand as of December 31, 2016.


c.	Royalties:

The Company’s research and development efforts are financed, in part, through funding from the IIA and BIRD. Since the Company’s inception through December 31, 2016, the Company received funding from the IIA and BIRD in the total amount of $740 thousand and $500 thousand, respectively. Out of the $740 thousand in funding from the IIA, a total amount of $340 thousand were royalty bearing grants (as of December 31, 2016, the Company paid royalties to the IIA in the total amount of $50), while a total amount of $400 thousand was received in consideration of 5,237 convertible preferred A shares. The Company is obligated to pay royalties to the IIA, amounting to 3%-3.5% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. The Company was obligated to pay royalties to the BIRD amounting to 5% of the sales of the products and other related revenues generated from such projects, up to 150% of the grants received. During December 2014, the Company recorded a liability of $466 thousand as a settlement for the prepayment of amounts due under the agreement with BIRD, representing the full balance of the contingent liability related to grants received (including interest), which was paid in January 2015. Upon making this payment, the Company eliminated all future royalty obligations related to its anticipated revenues. These expenses are included in the cost of revenues in the consolidated statement of operations.

For the years ended December 31, 2016, 2015 and 2014, the royalties expenses recorded in cost of revenues amounted to $0, $0 and $204 thousand respectively.

As of December 31, 2016, the contingent liability to the IIA amounted to $290 thousand, and there was no contingent liability to the BIRD. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases:

(a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the R&D activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) If such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient.

d. Liens

In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests.

The Company's long-term other assets in the amount of $820 thousand have been pledged as security in respect of a guarantee granted to a third party. Such deposit cannot be pledged to others or withdrawn without the consent of such third party.


e.	Legal Claims:

Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of our defenses and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition.

As set forth below, between September 2016 and January 2017, eight substantially similar putative securities class actions were filed against the Company. Four of these actions have been dismissed on procedural grounds and four are pending, including two actions which have been consolidated and one action brought by the plaintiffs whose actions were dismissed.

•

Dismissed Actions: On September 20, November 3, November 9, and November 10, 2016, respectively, four putative class actions on behalf of alleged shareholders that purchased or acquired the Company's ordinary shares pursuant and/or traceable to the registration statement used in connection with the Company's IPO were commenced in the Superior Court of the State of California, County of San Mateo. The actions were filed against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. We refer to these actions as the California State Actions. The complaints in the California State Actions asserted various claims under the Securities Act. Each of the California State Actions was dismissed for lack of personal jurisdiction in January 2017.


•	Pending Actions:

◦

On or about October 31, 2016, a class action with claims substantially similar to the California State Actions was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3336), alleging claims under Section 11 of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against the Company and certain of the Company's current and former directors and officers.

◦

On or about November 30, 2016, a substantially similar class action was commenced in the Massachusetts Superior Court, Suffolk County, by a different plaintiff (Civ. Action No. 16-3670) alleging claims under Sections 11 and Section 15 of the Securities Act against the same defendants as in the action commenced on October 31, 2016, and also alleging claims under Section 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO. This action was ordered consolidated in the Massachusetts Superior Court, Suffolk County on January 9, 2017 with the action commenced on October 31, 2016, and the two actions are referred to as the Consolidated Massachusetts State Court Actions.

◦

On or about January 24, 2017, a substantially similar class action was commenced in the United States District Court for the Northern District of California (Case No. 3:17-cv-362) alleging the same claims against the same defendants as in the action commenced on November 30, 2016, except that the Section 15 claim was not asserted against the underwriters, and the Section 11 and Section 15 claims were also asserted against certain entities referred to as the Venture Capital Defendants, who are alleged in the complaint to have beneficially owned, directly or indirectly, approximately 51% of the Company’s stock upon the closing of the IPO. This action is referred to as the California Federal Court Action.

◦

On or about January 31, 2017, a substantially similar class action was commenced in the United States District Court for the District of Massachusetts (Case No. 1:17-cv-10169) by the same plaintiffs who commenced the California State Court Actions, and one additional plaintiff, alleging claims under Section 11 and 12(a)(2) of the Securities Act against the Company, certain of the Company's current and former directors and officers, and the underwriters of the Company's IPO, and alleging claims under Section 15 of the Securities Act against certain of the Company's current and former directors and officers. This action is referred to as the Massachusetts Federal Court Action.

The plaintiffs in the Consolidated Massachusetts State Court Actions are expected to file a consolidated amended complaint on or about March 13, 2017. The Company has not yet responded to the complaints in the California Federal Court Action and the Massachusetts Federal Court Action.

The complaints in all of the actions listed above allege that the Company's registration statement used in connection with its IPO failed to disclose that the Company was unprepared or unable to comply with certain regulatory special controls and to provide the FDA with a post-market surveillance study on the Company's ReWalk Personal device, and that, as a result of such alleged omission, the plaintiffs suffered damages. The Company believes that the allegations made in the complaints are without merit and intends to defend itself vigorously against the complaints relating to the four pending actions.

Based on information currently available and the early stage of the litigation, the Company is unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to these lawsuits; therefore, no litigation reserve has been recorded in the Company's consolidated balance sheets as of December 31, 2016. The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable.

SHAREHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHAREHOLDERS' EQUITY

SHAREHOLDERS’ EQUITY


a.	Ordinary shares:

The ordinary shares of the Company confer on the holders thereof voting rights, rights to receive dividends and rights to participate in distribution of assets upon liquidation after any outstanding preferred shares receive their preference amount. The ordinary A shares and ordinary B shares were restated as ordinary shares in accordance with the following:

On August 26, 2014, in a duly convened extraordinary general meeting of the shareholders of the Company, the shareholders (i) duly approved an amendment of the Company's Articles of Association which subsequently entered effect upon the Company's initial public offering, under which the Company's authorized share capital was increased and restated as NIS 2,500,000 divided into 250,000,000 ordinary shares, par value NIS 0.01, and (ii) ratified an updated capitalization table of the Company, which represented each shareholder's holdings in the Company following the aforementioned restatement of the Company's authorized share capital.


b.	All ordinary shares, options, exercise prices and loss per share amounts have been adjusted retroactively for all periods presented in these financial statements, to reflect the 17-to-1 bonus share issuance (equivalent to an 18-for-1 share split) effected on August 26, 2014.


c.	Equity raise:

1.At-the-market offering program:

On May 10, 2016, the Company entered into the Equity Distribution Agreement with Piper Jaffray pursuant to which it may offer and sell, from time to time, ordinary shares having an aggregate offering price of up to $25 million, through Piper Jaffray acting as its agent. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Jaffray will use its commercially reasonable efforts to sell on the Company’s behalf all of the ordinary shares requested to be sold by the Company, consistent with its normal trading and sales practices. Piper Jaffray may also act as principal in the sale of ordinary shares under the Equity Distribution Agreement. Sales may be made under the Company's registration statement on Form S-3, which was declared effective on May 9, 2016, in what may be deemed “at-the-market” equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Sales may be made directly on or through the Nasdaq Global Market, the existing trading market for the Company's ordinary shares, to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or any other method permitted by law, including in privately negotiated transactions. Piper Jaffray is entitled to compensation at a fixed commission rate of 3.0% of the gross sales price per share sold through it as agent under the Equity Distribution Agreement. Where Piper Jaffray acts as principal in the sale of ordinary shares under the Equity Distribution Agreement, such rate of compensation will not apply, but in no event will the total compensation of Piper Jaffray, when combined with the reimbursement of Piper Jaffray for the out-of-pocket fees and disbursements of its legal counsel, exceed 8.0% of the gross proceeds received from the sale of the ordinary shares. The Company is not required to sell any of its ordinary shares at any time.

As of December 31, 2016, the Company had sold 692,062 ordinary shares under the ATM Offering Program for gross proceeds of $4.6 million and net proceeds to the Company of $4.1 million (after commissions, fees and expenses). Additionally, as of that date, the Company had paid Piper Jaffray compensation of $137 thousand and had incurred total expenses of approximately $468 thousand in connection with the ATM Offering Program.

2. Follow-on Offering

On October 27, 2016, the Company has entered into the Underwriting Agreement with Oppenheimer, in connection with the Company's follow-on public offering of 3,250,000 units, each consisting of one ordinary share and 0.75 of a warrant to purchase one ordinary share. Each unit was sold to the public at a price of $3.75 per unit. The units were not issued or certificated, and the ordinary shares and warrants underlying the units were immediately separable and issued separately. The warrants are not listed on the Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system. The ordinary shares and the warrants underlying the units and the ordinary shares issuable upon exercise of the warrants are registered under the Securities Act on the Company's Form S-3.

The offering closed on November 1, 2016. The Company's gross proceeds were $12.2 million. The Company's estimated net aggregate proceeds, after deducting underwriting discounts and commissions and estimated expenses, were $11.1 million. The Company also granted Oppenheimer an option to purchase up to 487,500 additional units at the public offering price, less the underwriting discount, for 30 days after October 27, 2016. Oppenheimer did not exercise these options. All estimates of net aggregate proceeds assume that none of the Warrants issued in the offering will be exercised.


d.	Share Option Plans:

On March 30, 2012, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2012 Equity Incentive Plan.

On August 19, 2014, the Company’s board of directors adopted the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan or the "Plan". The Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, cash-based awards, other stock-based awards and dividend equivalents to the Company’s and its affiliates’ respective employees, non-employee directors and consultants.

Starting in 2014, the Company grants to directors and employees RSUs under this Plan. An RSU award is an agreement to issue shares of our common stock at the time the award is vested.

As of December 31, 2016 and 2015, the Company had reserved 380,153 and 420,469 shares of ordinary shares, respectively, available for issuance to employees, directors, officers and non-employees of the Company.

The share reserve pool will increase on January 1 of each calendar year during the term of the 2014 Plan in an amount equal to the lesser of: (x) 972,000, (y) 4% of the total number of shares outstanding on December 31 of the immediately preceding calendar year, and (z) an amount determined by the Company's board of directors.

The options generally vest over four year, with certain options granted to non-employee directors during the fiscal year ended December 31, 2016, vesting over one year.

Any option that is forfeited or canceled before expiration becomes available for future grants under the Plan.

A summary of employee share options and RSUs activity during the fiscal year ended 2016 is as follows:



	Year Ended December 31, 2016
	Number		Average exercise price		Average remaining contractual life (years) (1)	Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at the beginning of the year	1,853,369		6.12		8.37	17,048
Options granted	391,285		9.25
RSUs granted	177,528		—
Options exercised (2)	(104,555	)	$	1.29
RSUs vested (2)	(37,704	)	$	—
RSUs forfeited	(1,487	)	$	—
Options forfeited	(27,422	)	$	9.74

Options and RSUs outstanding at the end of the year	2,251,014		6.47		7.80	1,740

Options and RSUs vested and expected to vest	2,208,737		6.47		7.79	1,700

Options exercisable at the end of the year	997,977		5.42		6.89	939


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.


(2)	During the fiscal year ended December 31, 2016, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 128,496 ordinary shares.

The weighted average grant date fair values of options granted during the fiscal year ended December 31, 2016, 2015 and 2014 were $4.75, $5.36 and $4.74 respectively. The weighted average grant date fair values of RSUs granted during the fiscal year ended December 31, 2016, 2015 and 2014,were $9.28, $20.77 and $20.97 respectively.

The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders, which hold options with positive intrinsic value, exercised their options on the last date of the exercise period. Total intrinsic value of options exercised for the year ended December 31, 2016, 2015 and 2014 were $844 thousand, $2.1 million and $38 thousand, respectively. Total fair value of shares vested during the year ended December 31, 2016 , 2015 and 2014 were $3,626 thousand, $2,164 thousand and $655 thousand respectively. As of December 31, 2016, there were $7.8 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2012 and 2014 Plans. This cost is expected to be recognized over a period of approximately 2.5 years.

The number of options and RSUs outstanding as of December 31, 2016 is set forth below, with options separated by range of exercise price:



Range of exercise price	Options and RSUs Outstanding as of December 31, 2016	Weighted average remaining contractual life (years) (1)	Options and RSUs outstanding as of December 31, 2016	Weighted average remaining contractual life (years) (1)
RSUs only	226,598	—	—	—
$0.82	34,377	4.03	34,377	4.03
$1.32	342,390	5.45	338,145	5.43
$1.48	403,125	7.03	281,243	7.03
$6.80-$8.99	761,211	8.93	195,249	8.86
$9.22-$10.98	223,056	9.35	6,273	9.27
$19.62-$20.97	260,257	7.98	142,690	7.98
	2,251,014	7.80	997,977	6.89


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.


e.	Options issued to consultants:

The Company’s outstanding options and RSUs granted to non-employees as of December 31, 2016 were as follows:



Issuance date	Options for shares of ordinary share	Exercise price per share		Options exercisable	Exercisable through
	(number)			(number)
March 12, 2007	3,454	$	—	3,454	March 12, 2017

On May 28, 2016, the Company entered into an agreement (the “Consulting Agreement”) with a separate non-employee consultant (the “Consultant”), under which the Consultant agreed to assist the Company in commercially promoting and expanding insurance coverage of the Company’s ReWalk devices. Compensation under the Consulting Agreement is due and payable only if the Consultant is successful, and will consist of agreed amounts in cash or ordinary shares and a percentage of certain sales resulting from the Consultant’s efforts. Additionally, the Company has agreed to pay the Consultant 10 percent of the increase in the Company’s market capitalization following the dates when coverage becomes active under national insurance policies that the Consultant secures for the Company. The increase in the Company’s market capitalization will be determined based on the increase between the average closing price over the ten days before disclosure of a relevant coverage decision and the average closing price over the ten days commencing 80 days after such disclosure. These variable payments, which will be made only for the first five national insurance policies the Consultant attains for the Company, (1) may be made in cash or stock at the Company’s choice and (2) may not exceed (i) $6.0 million for the date that the first national coverage policy takes effect, (ii) $5.0 million for the date that the second national coverage policy takes effect and (iii) $2.0 million for each of the dates that the next three national coverage policies take effect. The Company may need to seek shareholder approval pursuant to the rules of The Nasdaq Stock Market LLC should the Company elect to make such payments in stock. The Consulting Agreement has a term of 12 months, which will extend to 18 months if the Consultant secures a national coverage policy with certain insurers in the first 12 months and to 24 months if the Consultant secures at least two more national coverage policies within the first 18 months. Due to the fact that the compensation under the Consulting Agreement is based on achievement, the Company had not made any cash payments or issued any ordinary shares to the Consultant under the Consulting Agreement as of December 31, 2016.


f.	Warrants to purchase ordinary shares

During the fiscal year ended December 31, 2016, a total of 138,702 warrants were exercised on a cashless basis into 45,116 ordinary shares.

The following table summarizes information about warrants outstanding and exercisable as of December 31, 2016:



Issuance date	Warrants outstanding	Exercise price per warrant		Warrants exercisable	Exercisable through
	(number)			(number)
July 14, 2014 (1)	403,804	$	10.08	403,804	July 13, 2018
December 30, 2015 (2)	119,295	$	9.64	119,295	See footnote (2)
November 1, 2016 (3)	2,437,500	$	4.75	2,437,500	November 1, 2021
December 28, 2016 (4)	47,717	$	9.64	47,717	See footnote (2)
	3,008,316			3,008,316

(1) Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round.

(2) Represents warrants issuable upon the exercise of warrants to purchase ordinary shares at an exercise price of $9.64 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of December 31, 2016.

(3) Represents warrants issued as part of our follow-on offering in November 2016.

(4) Represents warrants in the amount of 47,717 ordinary shares were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 2 for exercisability terms.


g.	Share-based compensation expense for employees and non-employees:

The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows:



	Year Ended December 31,
	2016		2015		2014
Cost of revenues	$	108	$	64	$	33
Research and development, net	559		425		4,364
Sales and marketing, net	811		571		275
General and administrative	1,920		1,285		507

Total	$	3,398	$	2,345	$	5,179

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	12 Months Ended
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	Dec. 31, 2016
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into the “Collaboration Agreement” and License Agreement with Harvard. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. The Collaboration Agreement will expire on May 16, 2021. Under the License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of December 31, 2016 the Company did not achieve any of these milestones, and given the early stage of the License Agreement, the Company cannot anticipate the likelihood that the milestones will be achieved. Moreover, since such royalties are dependent on future product sales which are neither determinable nor reasonably estimable, these royalty payments are not recorded on the Company's consolidated financial statements as of December 31, 2016. The Company's total payment obligation under the Collaboration Agreement and of the License Agreement is $6.3 million, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expense in the amount of $1.7 million which is part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement for the fiscal year ended December 31, 2016.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References + Details

INCOME TAXES

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

INCOME TAXES

The Company’s subsidiaries are separately taxed under the domestic tax laws of the jurisdiction of incorporation of each entity.


a.	Corporate tax rates in Israel:

Presented hereunder are the tax rates relevant to the Company in the years 2014-2016:

The Israeli statutory corporate tax rate was 26.5% in 2015 and 2014, On January 4, 2016, the statutory tax rate was changed to 25% following a reduction of corporate tax by the government.

In December 2016, the Israeli Parliament approved the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which reduces the corporate income tax rate to 24% (instead of 25%) effective from January 1, 2017 and to 23% effective from January 1, 2018.


b.	Loss before taxes on income is comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Domestic	$	(32,642	)	$	(25,485	)	$	(21,743	)
Foreign	142			123			120
	$	(32,500	)	$	(25,362	)	$	(21,623	)


c.	Taxes on income are comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Current	$	8		$	114		$	76
Deferred	(5		)	(61		)	(60		)
Prior year taxes	—			—			29
	$	3		$	53		$	45



	Year Ended December 31,
	2016		2015		2014
Domestic	$	—	$	—	$	—
Foreign	3		53		45

	$	3	$	53	$	45


d.	Deferred income taxes:

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets as of December 31, 2016 and 2015 are derived from temporary differences.

In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company’s history of losses, the Company established a full valuation allowance for RRL.

Undistributed earnings of certain subsidiaries as of December 31, 2016 were immaterial. The Company intends to reinvest these earnings indefinitely in the foreign subsidiaries. As a result, the Company has not provided for any deferred income taxes.



	December 31,
	2016			2015
Carry forward tax losses	$	20,938		$	14,961
Research and development carry forward expenses-temporary differences	1,551			1,176
Accrual and reserves	223			206

Deferred tax assets before valuation allowance	22,712			16,343
Valuation allowance	(22,560		)	(16,196		)

Net deferred tax assets	$	152		$	147

The net changes in the total valuation allowance for each of the years ended December 31, 2016, 2015 and 2014, are comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Balance at beginning of year	$	(16,196	)	$	(10,089	)	$	(6,219	)
Changes due to amendments to tax laws and exchange rate differences	917			—			—
Additions during the year	(7,281		)	(6,107		)	(3,870		)
Balance at end of year	$	(22,560	)	$	(16,196	)	$	(10,089	)


e.	Reconciliation of the theoretical tax expenses:

A reconciliation between the theoretical tax expense, assuming all income is taxed at the statutory tax rate applicable to income of the Company, and the actual tax expense (benefit) as reported in the consolidated statements of operations is as follows:



	Year Ended December 31,
	2016			2015			2014
Loss before taxes, as reported in the consolidated statements of operations	$	(32,500	)	$	(25,362	)	$	(21,623	)

Statutory tax rate	25.0		%	26.5		%	26.5		%

Theoretical tax benefits on the above amount at the Israeli statutory tax rate	$	(8,125	)	$	(6,721	)	$	(5,730	)
Income tax at rate other than the Israeli statutory tax rate	10			16			12
Non-deductible expenses including equity based compensation expenses and other	857			651			1,864
Operating losses and other temporary differences for which valuation allowance was provided	7,281			6,107			3,870
Other	(20		)	—			—
Taxes in respect of prior years	—			—			29

Actual tax expense	$	3		$	53		$	45


f.	Foreign tax rates:

Taxable income of RRI was subject to tax at the rate of 40% in 2016, 2015, and 2014.

Taxable income of RRG was subject to tax at the rate of 30% in 2016, 2015, and 2014.


g.	Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):

Conditions for entitlement to the benefits:

Under the Investment Law, in 2012 the Company elected “Beneficiary Enterprise” status which provides certain benefits, including tax exemptions and reduced tax rates. Income not eligible for Beneficiary Enterprise benefits is taxed at a regular rate.

Income derived from Beneficiary Enterprise from productive activity will be exempt from tax for ten years from the year in which the Company first has taxable income, providing that 12 years have not passed from the beginning of the year of election. In the event of a dividend distribution from income that is exempt from company tax, as aforementioned, the Company will be required to pay tax of 10%- 25% on that income.

In the event of distribution of dividends from the said tax-exempt income, the amount distributed will be subject to corporate tax at the rate ordinarily applicable to the Beneficiary Enterprise’s income. Tax-exempt income generated under the Company’s “Beneficiary Enterprise” program will be subject to taxes upon dividend distribution or complete liquidation.

The entitlement to the above benefits is conditional upon the Company’s fulfilling the conditions stipulated by the Law and regulations published thereunder.

On December 29, 2010, the Knesset approved an additional amendment to the Law for the Encouragement of Capital Investments, 1959. According to the amendment, a reduced uniform corporate tax rate for exporting industrial enterprises (over 25%) was established. The reduced tax rate will not be program dependent and will apply to the industrial enterprise’s entire income. The tax rates for industrial enterprises have been reduced. In August 2013, the Israeli Knesset approved an amendment to the Investment Law, pursuant to which the rates for development area A will be 9% and for the rest of the country- 16% in 2014 and thereafter. The Amendment also prescribes that any dividends distributed to individuals or foreign residents from a preferred enterprise's earnings as above will be subject to taxes at a rate of 20% (subject to tax treaty benefits)

In December 2016, the Economic Efficiency Law (Legislative Amendments for Applying the Economic Policy for the 2017 and 2018 Budget Years), 2016 which includes Amendment 73 to the Law for the Encouragement of Capital Investments ("the Amendment") was published. According to the Amendment, a preferred enterprise located in development area A will be subject to a tax rate of 7.5% instead of 9% effective from January 1, 2017 (and thereafter the tax rate applicable to preferred enterprises located in other areas remains at 16%).

The Company has examined the effect of the adoption of the Amendment on its financial statements, and as of the date of the publication of the financial statements, the Company estimates that it will not apply the Amendment. The Company’s estimate may change in the future.


h.	Tax assessments:

RRL has had final tax assessments up to and including the 2012 tax year.

Each RRI and RRG have not had final tax assessment, since its inception.


i.	Net operating carry-forward losses for tax purposes:

As of December 31, 2016, RRL has carry-forward losses amounting to approximately $83.8 million, which can be carried forward for an indefinite period.

FINANCIAL EXPENSES, NET

12 Months Ended

Dec. 31, 2016

Other Income and Expenses [Abstract]

FINANCIAL EXPENSES, NET

The components of financial expenses, net were as follows:



	Year Ended December 31,
	2016			2015			2014
Foreign currency transactions and other	$	85		$	170		$	200
Financial expenses related to loan agreement with Kreos	1,976			—			100
Bank commissions	34			36			36
Expenses (income) related to hedging transactions	(36		)	(18		)	61
Issuance of warrants to purchase convertible preferred share	—			—			835
Revaluation of fair value of warrants to purchase convertible preferred share	—			—			(776		)
Issuance of convertible preferred shares	—			—			1,114
Issuance cost related to warrants liability	—			—			128
	$	2,059		$	188		$	1,698

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA

Summary information about geographic areas:

ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling systems and services (see Note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas:



	Year Ended December 31,
	2016		2015		2014
Revenues based on customer’s location:
Israel	$	—	$	—	$	—
United States	3,741		2,439		2,186
Europe	1,144		820		1,254
Asia-Pacific	984		487		511

Total revenues	$	5,869	$	3,746	$	3,951



	December 31,
	2016		2015
Long-lived assets by geographic region:
Israel	$	476	$	605
United States	565		483
Germany	217		240

	$	1,258	$	1,328

(*) Long-lived assets are comprised of property and equipment, net.

Major customer data as a percentage of total revenues:



	Year Ended December 31,
	2016		2015		2014
Customer A	33.3	%	14.8	%	15.1	%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS a. On January 9, 2017, the Company has announced its plan to reduce total operating expenses in 2017 by up to 30% as compared to 2016. These reductions will be achieved through a combination of targeted savings, including the completion of specific projects focused on quality improvement initiatives and efforts to reduce overall product cost, a realignment of and reduction in staffing to match the Company’s 2017 business goals, and a reduction in other corporate spending. b. See note 7e for information on developments in legal proceedings in 2017. .

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Use of Estimates

Financial Statements in U.S. Dollars

Financial Statements in U.S. Dollars:

Principles of Consolidation

Principles of Consolidation:

Cash Equivalents

Cash Equivalents:

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with original maturities of three months or less, at the date acquired.

Inventories

Inventories:

Inventories are stated at the lower of cost or market value. Inventory reserves are provided to cover risks arising from slow-moving items or technological obsolescence.

Cost is determined as follows:

Related party

Related party:

The Company has a substantial shareholder named Yaskawa Electric Corporation (“YEC”).

Property and Equipment

Property and Equipment:



	%
Computer equipment	20-33 (mainly 33)
Office furniture and equipment	6 - 10 (mainly 10)
Machinery and laboratory equipment	15
Field service units	50
Leasehold improvements	Over the shorter of the lease term or estimated useful life

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets:

Other long term assets

Other long term assets:

Other long term assets include long-term prepaid expenses and deposits for offices and cars leasing.

Revenue Recognition

Revenue Recognition:

The Company and its subsidiaries generate revenues from sales of products. The Company and its subsidiaries sell their products through a direct sales force and through distributors.

Deferred revenue includes primarily unearned amounts received in respect of service contracts but not yet recognized as revenues.

Accounting for Share-Based Compensation

Accounting for Share-Based Compensation:

Following the IPO in September 2014, the fair value of ordinary shares is observable as they are publicly traded.

The fair value of Restricted Stock Units (RSUs) granted is determined based on the price of the Company's ordinary shares on the date of grant.

The fair value for options granted in 2016, 2015 and 2014 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions:



	December 31,
	2016	2015	2014
Expected volatility	53%-60%	60%	60%-70%
Risk-free rate	1.16%-1.60%	1.60%-1.95%	1.74%-1.95%
Dividend yield	—%	—%	—%
Expected term (in years)	5.31 - 6.11	5.73 - 6.11	5.81 - 6.11
Share price	$6.80 - $11.88	$7.30 - $20.97	$1.49 - $20.77

Research and Development Costs

Research and Development Costs:

Income Taxes

Warranty

Warranty:

Concentrations of Credit Risks

Concentrations of Credit Risks:

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and trade receivables.

Accrued Severance Pay

Accrued Severance Pay:

Fair Value Measurements

Fair Value Measurements:


•	Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;


•	Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and


•	Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.

The carrying amounts of cash and cash equivalents, short term deposits, trade receivables and trade payables approximate their fair value due to the short-term maturity of such instruments.

Basic and Diluted Net Loss Per Share

Basic and Diluted Net Loss Per Share:

Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period.

Contingent liabilities

Government grants

New Accounting Pronouncements


i.	Revenues:

ii. Going concern:


ii.	Inventory:


iii.	Leases:


iv.	Share Based Compensation:


v.	Cash Flow:

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of Property and Equipment Estimated Useful Lives



	%
Computer equipment	20-33 (mainly 33)
Office furniture and equipment	6 - 10 (mainly 10)
Machinery and laboratory equipment	15
Field service units	50
Leasehold improvements	Over the shorter of the lease term or estimated useful life

Schedule of Assumptions Used to Determine the Fair Value of Options Granted

The fair value for options granted in 2016, 2015 and 2014 is estimated at the date of grant using a Black-Scholes-Merton option pricing model with the following assumptions:



	December 31,
	2016	2015	2014
Expected volatility	53%-60%	60%	60%-70%
Risk-free rate	1.16%-1.60%	1.60%-1.95%	1.74%-1.95%
Dividend yield	—%	—%	—%
Expected term (in years)	5.31 - 6.11	5.73 - 6.11	5.81 - 6.11
Share price	$6.80 - $11.88	$7.30 - $20.97	$1.49 - $20.77

Rollforward of Standard Warranty



	US Dollars in thousands
Balance at December 31, 2015	$	502
Provision	400
Usage	(404		)
Balance at December 31, 2016	$	498

Schedule of Computation of the Basic and Diluted Net Loss per Ordinary Share

The following table sets forth the computation of the Company’s basic and diluted net loss per ordinary share (in thousands, except share and per share data):



	Year ended December 31
	2016			2015			2014
Net loss	$	(32,503	)	$	(25,415	)	$	(21,668	)
Convertible preferred shares dividend	—			—			(2,229		)

Net loss attributable to ordinary shares	(32,503		)	(25,415		)	(23,897		)
Shares used in computing net loss per ordinary shares, basic and diluted	13,178,107			12,115,038			3,766,694

Net loss per ordinary share, basic and diluted	$	(2.47	)	$	(2.10	)	$	(6.34	)

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

12 Months Ended

Dec. 31, 2016

Prepaid Expense and Other Assets, Current [Abstract]

Schedule of Prepaid Expenses and Other Current Assets

The components of prepaid expenses and other current assets are as follows (in thousands):



	December 31,
	2016		2015
Government institutions	$	113	$	209
Prepaid expenses	355		316
Deposit	—		43
Deferred tax	152		147
Other assets	671		512

	$	1,291	$	1,227

INVENTORIES (Tables)

12 Months Ended

Dec. 31, 2016

Inventory Disclosure [Abstract]

Schedule of Inventories

The components of inventory are as follows (in thousands):



	December 31,
	2016		2015
Raw materials	$	—	$	450
Finished products	3,264		2,084

	$	3,264	$	2,534

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended

Dec. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, net

The components of property and equipment, net are as follows (in thousands):



	December 31,
	2016		2015
Cost:
Computer equipment	$	709	$	656
Office furniture and equipment	293		286
Machinery and laboratory equipment	573		471
Field service units	771		575
Leasehold improvements	358		113

	2,704		2,101



	December 31,
	2016		2015
Accumulated depreciation	1,446		773

Property and equipment, net	$	1,258	$	1,328

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES (Tables)

12 Months Ended

Dec. 31, 2016

Debt Disclosure [Abstract]

Assumptions Used to Estimate the Value of the Company's Warrants to Purchase Ordinary Shares



	December 28, 2016		December 30, 2015
Expected volatility	53	%	60	%
Risk-free rate	2.51	%	2.52	%
Dividend yield	—	%	—	%
Expected term (in years)	9		10

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Operating Lease Commitments



2017	495
2018	547
2019	558
2020	567
2021 and Thereafter	2,219
Total	$	4,386

SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)

12 Months Ended

Dec. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Employee Share Option and RSU Activity

A summary of employee share options and RSUs activity during the fiscal year ended 2016 is as follows:



	Year Ended December 31, 2016
	Number		Average exercise price		Average remaining contractual life (years) (1)	Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at the beginning of the year	1,853,369		6.12		8.37	17,048
Options granted	391,285		9.25
RSUs granted	177,528		—
Options exercised (2)	(104,555	)	$	1.29
RSUs vested (2)	(37,704	)	$	—
RSUs forfeited	(1,487	)	$	—
Options forfeited	(27,422	)	$	9.74

Options and RSUs outstanding at the end of the year	2,251,014		6.47		7.80	1,740

Options and RSUs vested and expected to vest	2,208,737		6.47		7.79	1,700

Options exercisable at the end of the year	997,977		5.42		6.89	939


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.


(2)	During the fiscal year ended December 31, 2016, the aggregate number of ordinary shares that were issued pursuant to RSUs that became vested and options that were exercised on a net basis was 128,496 ordinary shares.

Schedule of Options and RSUs Outstanding Which Have Been Separated Into Ranges of Exercise Price

The number of options and RSUs outstanding as of December 31, 2016 is set forth below, with options separated by range of exercise price:



Range of exercise price	Options and RSUs Outstanding as of December 31, 2016	Weighted average remaining contractual life (years) (1)	Options and RSUs outstanding as of December 31, 2016	Weighted average remaining contractual life (years) (1)
RSUs only	226,598	—	—	—
$0.82	34,377	4.03	34,377	4.03
$1.32	342,390	5.45	338,145	5.43
$1.48	403,125	7.03	281,243	7.03
$6.80-$8.99	761,211	8.93	195,249	8.86
$9.22-$10.98	223,056	9.35	6,273	9.27
$19.62-$20.97	260,257	7.98	142,690	7.98
	2,251,014	7.80	997,977	6.89


(1)	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

Schedule of outstanding Options and RSUs Granted to Non-employees

The Company’s outstanding options and RSUs granted to non-employees as of December 31, 2016 were as follows:



Issuance date	Options for shares of ordinary share	Exercise price per share		Options exercisable	Exercisable through
	(number)			(number)
March 12, 2007	3,454	$	—	3,454	March 12, 2017

Schedule of Warrants Outstanding and Exercisable

The following table summarizes information about warrants outstanding and exercisable as of December 31, 2016:



Issuance date	Warrants outstanding	Exercise price per warrant		Warrants exercisable	Exercisable through
	(number)			(number)
July 14, 2014 (1)	403,804	$	10.08	403,804	July 13, 2018
December 30, 2015 (2)	119,295	$	9.64	119,295	See footnote (2)
November 1, 2016 (3)	2,437,500	$	4.75	2,437,500	November 1, 2021
December 28, 2016 (4)	47,717	$	9.64	47,717	See footnote (2)
	3,008,316			3,008,316

(1) Represents warrants to purchase ordinary shares at an exercise price of $10.08 per share, which were granted on July 14, 2014 as part of our series E investment round.

Schedule of Non-cash Share-based Compensation Expense

The Company recognized non-cash share-based compensation expense in the consolidated statements of operations as follows:



	Year Ended December 31,
	2016		2015		2014
Cost of revenues	$	108	$	64	$	33
Research and development, net	559		425		4,364
Sales and marketing, net	811		571		275
General and administrative	1,920		1,285		507

Total	$	3,398	$	2,345	$	5,179

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2016

Income Tax Disclosure [Abstract]

Schedule of Profit (Loss) Before Taxes on Income

oss before taxes on income is comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Domestic	$	(32,642	)	$	(25,485	)	$	(21,743	)
Foreign	142			123			120
	$	(32,500	)	$	(25,362	)	$	(21,623	)

Schedule of Taxes on Income

Taxes on income are comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Current	$	8		$	114		$	76
Deferred	(5		)	(61		)	(60		)
Prior year taxes	—			—			29
	$	3		$	53		$	45



	Year Ended December 31,
	2016		2015		2014
Domestic	$	—	$	—	$	—
Foreign	3		53		45

	$	3	$	53	$	45

Schedule of Deferred Income Taxes



	December 31,
	2016			2015
Carry forward tax losses	$	20,938		$	14,961
Research and development carry forward expenses-temporary differences	1,551			1,176
Accrual and reserves	223			206

Deferred tax assets before valuation allowance	22,712			16,343
Valuation allowance	(22,560		)	(16,196		)

Net deferred tax assets	$	152		$	147

Summary of Net Changes in Total Valuation Allowance

The net changes in the total valuation allowance for each of the years ended December 31, 2016, 2015 and 2014, are comprised as follows:



	Year Ended December 31,
	2016			2015			2014
Balance at beginning of year	$	(16,196	)	$	(10,089	)	$	(6,219	)
Changes due to amendments to tax laws and exchange rate differences	917			—			—
Additions during the year	(7,281		)	(6,107		)	(3,870		)
Balance at end of year	$	(22,560	)	$	(16,196	)	$	(10,089	)

Schedule of Reconciliation Between the Theoretical Tax Expense and the Actual Tax Expense (Benefit)



	Year Ended December 31,
	2016			2015			2014
Loss before taxes, as reported in the consolidated statements of operations	$	(32,500	)	$	(25,362	)	$	(21,623	)

Statutory tax rate	25.0		%	26.5		%	26.5		%

Theoretical tax benefits on the above amount at the Israeli statutory tax rate	$	(8,125	)	$	(6,721	)	$	(5,730	)
Income tax at rate other than the Israeli statutory tax rate	10			16			12
Non-deductible expenses including equity based compensation expenses and other	857			651			1,864
Operating losses and other temporary differences for which valuation allowance was provided	7,281			6,107			3,870
Other	(20		)	—			—
Taxes in respect of prior years	—			—			29

Actual tax expense	$	3		$	53		$	45

FINANCIAL EXPENSES, NET (Tables)

12 Months Ended

Dec. 31, 2016

Other Income and Expenses [Abstract]

Schedule of financial expenses (income), net

The components of financial expenses, net were as follows:



	Year Ended December 31,
	2016			2015			2014
Foreign currency transactions and other	$	85		$	170		$	200
Financial expenses related to loan agreement with Kreos	1,976			—			100
Bank commissions	34			36			36
Expenses (income) related to hedging transactions	(36		)	(18		)	61
Issuance of warrants to purchase convertible preferred share	—			—			835
Revaluation of fair value of warrants to purchase convertible preferred share	—			—			(776		)
Issuance of convertible preferred shares	—			—			1,114
Issuance cost related to warrants liability	—			—			128
	$	2,059		$	188		$	1,698

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Summary of Revenues within Geographic Areas

The following is a summary of revenues within geographic areas:



	Year Ended December 31,
	2016		2015		2014
Revenues based on customer’s location:
Israel	$	—	$	—	$	—
United States	3,741		2,439		2,186
Europe	1,144		820		1,254
Asia-Pacific	984		487		511

Total revenues	$	5,869	$	3,746	$	3,951

Summary of Long-Lived Assets by Geographic Region



	December 31,
	2016		2015
Long-lived assets by geographic region:
Israel	$	476	$	605
United States	565		483
Germany	217		240

	$	1,258	$	1,328

(*) Long-lived assets are comprised of property and equipment, net.

Schedule of Major Customer data as a Percentage of Total Revenues

Major customer data as a percentage of total revenues:



	Year Ended December 31,
	2016		2015		2014
Customer A	33.3	%	14.8	%	15.1	%

GENERAL (Details) $ in Thousands	12 Months Ended
GENERAL (Details) $ in Thousands	Dec. 31, 2016 USD ($) subsidiary product	Dec. 31, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of wholly-owned subsidiaries \| subsidiary	2
Number of products \| product	2
Accumulated deficit \| $	$ 106,492	$ 73,989

GENERAL - Issuance of Stock (Details) - USD ($)

1 Months Ended

8 Months Ended

12 Months Ended

Oct. 27, 2016

Nov. 30, 2016

Dec. 31, 2016

May 10, 2016

Subsidiary, Sale of Stock [Line Items]

Maximum amount which can be raised under ATM offering program

$ 25,000,000

Number of shares issuable per unit (in shares)

Number of warrants issued per unit (in shares)

0.75

ATM Offering Program

Subsidiary, Sale of Stock [Line Items]

Number of shares issued and sold (in shares)

^[1],[2],[3]

692,062.000

692,062

Gross proceeds from share issuance

$ 4,600,000

Total expenses incurred under ATM program

$ 468,000

468,000

Net proceeds from share issuance

^[2]

$ 4,099,000

ATM Offering Program | Weighted Average

Subsidiary, Sale of Stock [Line Items]

Price of shares issued (in USD per share)

$ 6.6

Follow-On Public Offering

Subsidiary, Sale of Stock [Line Items]

Net proceeds from share issuance

^[2]

$ 11,089,000

Number of units issued and sold (in shares)

3,250,000

Unit price (in USD per share)

$ 3.75

Gross proceeds from sale of shares

$ 12,200,000

Ordinary Share | ATM Offering Program

Subsidiary, Sale of Stock [Line Items]

Net proceeds from share issuance

^[1],[2],[3]

$ 2,000

Ordinary Share | Follow-On Public Offering

Subsidiary, Sale of Stock [Line Items]

Number of shares issued and sold (in shares)

^[1],[2],[3]

3,250,000

Net proceeds from share issuance

^[1],[2],[3]

$ 9,000

[1]	All shares amount have been restated to reflect an 18-for-1 share split split as of August 26, 2014, see Note 8b.
[2]	See note 8c.
[3]	The ordinary shares consist of two series, see note 8a.

GENERAL - Concentration Risk (Details) - Supplier Concentration Risk - Trade Payables - manufacturer	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Concentration Risk [Line Items]
Number of contract manufacturers	1
Concentration risk (as a percent)	12.00%	24.00%

SIGNIFICANT ACCOUNTING POLICIES - Other Narratives (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Inventories:
Wrote off inventory	$ 237,000	$ 127,000	$ 76,000
Impairment of Long-Lived Assets:
Impairment losses	$ 0	0	0
Accrued Severance Pay:
Percentage of monthly deposit by employees	8.33%
Severance pay expense	$ 226,000	$ 202,000	$ 170,000

SIGNIFICANT ACCOUNTING POLICIES - Related party (Details) - YEC - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related party [Line Items]
Revenues from related party	$ 295	$ 246	$ 394
Credit Concentration Risk
Related party [Line Items]
Related party receivables as a percent of trade receivables, net	24.20%	11.30%

SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2016
Computer equipment \| Minimum
Property and Equipment [Line Items]
Depreciation rate	20.00%
Computer equipment \| Maximum
Property and Equipment [Line Items]
Depreciation rate	33.00%
Office furniture and equipment \| Minimum
Property and Equipment [Line Items]
Depreciation rate	6.00%
Office furniture and equipment \| Maximum
Property and Equipment [Line Items]
Depreciation rate	10.00%
Machinery and laboratory equipment
Property and Equipment [Line Items]
Depreciation rate	15.00%
Field service units
Property and Equipment [Line Items]
Depreciation rate	50.00%

SIGNIFICANT ACCOUNTING POLICIES - Accounting for Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash compensation expenses	$ 3,398	$ 2,345	$ 5,179
Stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility		60.00%
Dividend yield	0.00%	0.00%	0.00%
Stock option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.00%		60.00%
Risk-free rate	1.16%	1.60%	1.74%
Expected term (in years)	5 years 3 months 22 days	5 years 8 months 23 days	5 years 9 months 22 days
Share price (in USD per share)	$ 6.80	$ 7.30	$ 1.49
Stock option \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	60.00%		70.00%
Risk-free rate	1.60%	1.95%	1.95%
Expected term (in years)	6 years 1 month 10 days	6 years 1 month 10 days	6 years 1 month 10 days
Share price (in USD per share)	$ 11.88	$ 20.97	$ 20.77

SIGNIFICANT ACCOUNTING POLICIES - Rollforward of Standard Warranty (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Accounting Policies [Abstract]
Term of standard warranty	2 years
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at December 31, 2015	$ 502
Provision	400
Usage	(404)
Balance at December 31, 2016	$ 498

SIGNIFICANT ACCOUNTING POLICIES - Concentration of Credit Risk (Details) $ in Thousands			12 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) customer	Dec. 31, 2016 USD ($) customer
Concentration Risk [Line Items]
Trade receivable, allowance for doubtful accounts	$ 333	$ 144	$ 333
Sales return reserve	$ 105	$ 0	$ 105
Customer Concentration \| Trade Receivables
Concentration Risk [Line Items]
Number of customers \| customer		1	1
Concentration risk (as a percent)	0.00%	21.00%

SIGNIFICANT ACCOUNTING POLICIES - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Net loss	$ (32,503)	$ (25,415)	$ (21,668)
Convertible preferred shares dividend	0	0	(2,229)
Net loss attributable to ordinary shares	$ (32,503)	$ (25,415)	$ (23,897)
Shares used in computing net loss per ordinary shares, basic and diluted (in shares)	13,178,107	12,115,038	3,766,694
Net loss per ordinary share, basic and diluted (in USD per share)	$ (2.47)	$ (2.10)	$ (6.34)

SIGNIFICANT ACCOUNTING POLICIES - Government grants (Details) - BIRD - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Government grants [Line Items]
Royalty-bearing grants expenses	$ 0	$ 214	$ 76
Royalties expenses	$ 0	$ 0	$ 204

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Prepaid Expense and Other Assets, Current [Abstract]
Government institutions	$ 113	$ 209
Prepaid expenses	355	316
Deposit	0	43
Deferred tax	152	147
Other assets	671	512
Prepaid expenses and other current assets	$ 1,291	$ 1,227

INVENTORIES (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Raw materials	$ 0	$ 450
Finished products	3,264	2,084
Inventories	$ 3,264	$ 2,534

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	$ 2,704	$ 2,101
Accumulated depreciation	1,446	773
Property and equipment, net	1,258	1,328
Depreciation expenses	696	438	$ 111
Computer equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	709	656
Office furniture and equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	293	286
Machinery and laboratory equipment
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	573	471
Field service units
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	771	575
Leasehold improvements
PROPERTY AND EQUIPMENT, NET [Line Items]
Property, plant and equipment, gross	$ 358	$ 113

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES - Loan Agreement, Narrative (Details)				12 Months Ended
	Dec. 28, 2016 USD ($)	Jan. 04, 2016 USD ($)	Dec. 30, 2015 USD ($)	Dec. 31, 2016 USD ($) payment	Dec. 28, 2016 USD ($)	Dec. 28, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Proceeds from long term loan				$ 20,000,000			$ 0	$ 0
Loan transaction fee				501,000			0	0
Interest expense				1,976,000			$ 0	$ 100,000
Term Loan \| Loan Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 20,000,000.0
Proceeds from long term loan	$ 8,000,000	$ 12,000,000
Remaining borrowing capacity under loan agreement				8,000,000.0
Minimum amount required to be raised in order to draw down remaining credit facility				$ 10,000,000.0
Loan term			24 months	36 months
Annual interest rate				10.75%
Number of monthly payments \| payment				24
Extended term				36 months
Minimum amount to be raised by issuance of capital stock for extended loan term				$ 20,000,000.0
Loan transaction fee		415,000			$ 441,000	$ 26,000
Advanced payment		$ 660,000
Transaction fee expenses	$ 140,000				$ 140,000	$ 140,000

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES - Warrants, Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Dec. 28, 2016	Jan. 04, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 30, 2015
Class of Warrant or Right [Line Items]
Proceeds from long term loan			$ 20,000	$ 0	$ 0
Term Loan \| Loan Agreement
Class of Warrant or Right [Line Items]
Proceeds from long term loan	$ 8,000	$ 12,000
Issuance expenses	$ 140
Ordinary Share
Class of Warrant or Right [Line Items]
Number of warrants issued (in shares)	47,717		167,012			119,295
Exercise price (in USD per share)						$ 9.64
Increase in warrants as a percentage of additional drawdowns			5.75%
Minimum percentage in acquired company required to prevent warrants from becoming exercisable			50.00%
Fair value of warrants	$ 78					$ 1,200
Issuance expenses	$ 2					$ 42

LOAN AGREEMENT WITH KREOS AND RELATED WARRANT TO PURCHASE ORDINARY SHARES - Assumptions Used to Estimate the Value of the Company's Warrants to Purchase Ordinary Shares (Details) - Ordinary Share	Dec. 28, 2016	Dec. 30, 2015
Class of Warrant or Right [Line Items]
Expected volatility	53.00%	60.00%
Risk-free rate	2.51%	2.52%
Dividend yield	0.00%	0.00%
Expected term (in years)	9 years	10 years

COMMITMENTS AND CONTINGENT LIABILITIES - Purchase and Lease Commitment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Purchase commitment
Outstanding purchase orders	$ 2,200
Lease commitment:
Total rent expenses	650	$ 260	$ 168
Maximum penalties payable on early release of agreement	$ 53

COMMITMENTS AND CONTINGENT LIABILITIES - Schedule of Future Minimum Operating Lease Commitments (Details) $ in Thousands	Dec. 31, 2016 USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2017	$ 495
2018	547
2019	558
2020	567
2021 and Thereafter	2,219
Total	$ 4,386

COMMITMENTS AND CONTINGENT LIABILITIES - Royalties (Details) $ in Thousands	12 Months Ended			186 Months Ended
	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2016 USD ($) shares
IIA
Royalties [Line Items]
Total funding amount received				$ 740
Royalty bearing grants				340
Royalties paid				50
Contingent liability	$ 290			290
Maximum portion of sale price paid in consideration for OCS-funded know-how	6
Transfer of know-how outside Israel approved, if portion of sale price paid by grant receipt does not exceed specified multiplier of grant received	3
IIA \| Minimum
Royalties [Line Items]
Royalty (as a percent)	3.00%
IIA \| Maximum
Royalties [Line Items]
Royalty (as a percent)	3.50%
Percentage of grant received considered to determine royalty fees	100.00%
IIA \| Series A preferred stock
Royalties [Line Items]
Amount received in consideration of convertible preferred shares				$ 400
Issuance of ordinary shares (in shares) \| shares				5,237
BIRD
Royalties [Line Items]
Total funding amount received				$ 500
Royalty (as a percent)	5.00%
Contingent liability			$ 466
Royalties expenses	$ 0	$ 0	$ 204
BIRD \| Maximum
Royalties [Line Items]
Royalty (as a percent)	150.00%

COMMITMENTS AND CONTINGENT LIABILITIES - Liens (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, collateral pledged	$ 820

COMMITMENTS AND CONTINGENT LIABILITIES - Legal Claims (Details)	2 Months Ended	5 Months Ended	6 Months Ended
	Nov. 10, 2016 action	Jan. 31, 2017 action	Feb. 17, 2017 action	Jan. 24, 2017	Dec. 31, 2016 USD ($)
Subsequent Event [Line Items]
Number of putative class actions brought against company	4
Litigation reserve \| $					$ 0
Subsequent Event
Subsequent Event [Line Items]
Number of putative class actions brought against company		8
Actions dismissed			4
Actions pending			4
Percentage of common stock owned by plaintiffs				51.00%
Consolidated Litigation \| Subsequent Event
Subsequent Event [Line Items]
Actions pending			2
Plaintiff's Actions Dismissed \| Subsequent Event
Subsequent Event [Line Items]
Actions pending			1

SHAREHOLDERS' EQUITY - Ordinary Shares, Narrative (Details) ₪ / shares in Units, $ in Thousands	Aug. 26, 2014 ILS (₪) ₪ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2016 ₪ / shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2015 ₪ / shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Ordinary shares, authorized amount	₪ 2,500,000	$ 45		$ 33
Ordinary shares, shares authorized (in shares) \| shares	250,000,000	250,000,000		250,000,000
Ordinary shares, par value (in NIS per share) \| ₪ / shares	₪ 0.01		₪ 0.01		₪ 0.01
Bonus share issuance ratio	17
Share split ratio	18

SHAREHOLDERS' EQUITY - Equity Raise, Narrative (Details) - USD ($)

1 Months Ended

8 Months Ended

12 Months Ended

Nov. 01, 2016

Oct. 27, 2016

Nov. 30, 2016

Dec. 31, 2016

May 10, 2016

Subsidiary, Sale of Stock [Line Items]

Maximum amount which can be raised under ATM offering program

$ 25,000,000

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

3.00%

Number of shares issuable per unit (in shares)

Number of warrants issued per unit (in shares)

0.75

Period of underwriter's option

30 days

ATM Offering Program

Subsidiary, Sale of Stock [Line Items]

Issuance of ordinary shares (in shares)

^[1],[2],[3]

692,062.000

692,062

Gross proceeds from share issuance

$ 4,600,000

Net proceeds from share issuance

^[2]

4,099,000

Issuance expenses

468,000

Total expenses incurred under ATM program

$ 468,000

468,000

ATM Offering Program | Piper Jaffray

Subsidiary, Sale of Stock [Line Items]

Issuance expenses

$ 137,000

Follow-On Public Offering

Subsidiary, Sale of Stock [Line Items]

Net proceeds from share issuance

^[2]

11,089,000

Issuance expenses

$ 1,099,000

Number of units issued (in shares)

3,250,000

Unit price (in USD per share)

$ 3.75

Gross proceeds from sale of shares

$ 12,200,000

Net proceeds from sale of shares

$ 11,100,000

Underwriting Option

Subsidiary, Sale of Stock [Line Items]

Number of units issued (in shares)

487,500

Maximum

Subsidiary, Sale of Stock [Line Items]

Stock issuance costs under equity distribution agreement as a percent of gross proceeds

8.00%

[1]	All shares amount have been restated to reflect an 18-for-1 share split split as of August 26, 2014, see Note 8b.
[2]	See note 8c.
[3]	The ordinary shares consist of two series, see note 8a.

SHAREHOLDERS' EQUITY - Share Option Plans, Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair values of options granted (in USD per share)	$ 4.75	$ 5.36	$ 4.74
Total intrinsic value of options exercised	$ 844,000	$ 2,100,000	$ 38,000
Fair value of shares vested during the year	3,626,000	$ 2,164,000	$ 655,000
Unrecognized compensation cost	$ 7,800,000
Period of recognition of unrecognized compensation cost	2 years 6 months
Employee and Non-employee Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	380,153	420,469
Increase in share reserve pool for future issuance, minimum annual increase (in shares)	972,000
Increase in share reserve pool for future issuance, annual increase as a percentage of total shares outstanding	4.00%
Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	4 years
Nonemployee Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair values of RSUs granted (in USD per share)	$ 9.28	$ 20.77	$ 20.97

SHAREHOLDERS' EQUITY - Summary of Employee Share Option and RSU Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
RSUs
Number
RSUs granted (in shares)	177,528
RSUs vested (in shares)	(37,704)
RSUs forfeited (in shares)	(1,487)
Options
Number
Options granted (in shares)	391,285
Options exercised (in shares)	(104,555)
Options forfeited (in shares)	(27,422)
Options exercisable at the end of the year (in shares)	997,977
Average exercise price
Options granted (in USD per share)	$ 9.25
Options exercised (in USD per share)	1.29
Options forfeited (in USD per share)	9.74
Options exercisable at the end of the year (in USD per share)	$ 5.42
Average remaining contractual life (years)
Options exercisable at the end of the year	6 years 10 months 21 days
Aggregate intrinsic value (in thousands)
Options exercisable at the end of the year	$ 939
Options and RSUs
Number
Options and RSU's outstanding at the beginning of the year (in shares)	1,853,369
Options and RSU's outstanding at the end of the year (in shares)	2,251,014	1,853,369
Options and RSUs vested and expected to vest (in shares)	2,208,737
Average exercise price
Options and RSUs outstanding at the beginning of the year (in USD per share)	$ 6.12
Options and RSUs outstanding at the end of the year (in USD per share)	6.47	$ 6.12
Options and RSUs vested and expected to vest (in USD per share)	$ 6.47
Average remaining contractual life (years)
Options and RSUs outstanding	7 years 9 months 18 days	8 years 4 months 13 days
Options and RSUs vested and expected to vest	7 years 9 months 15 days
Aggregate intrinsic value (in thousands)
Options and RSUs outstanding at beginning of year	$ 17,048
Options and RSUs outstanding at end of year	1,740	$ 17,048
Options and RSUs vested and expected to vest	$ 1,700
RSUs vested and options exercised (in shares)	128,496

SHAREHOLDERS' EQUITY - Schedule of Options and RSUs Outstanding Which have been Separated into Ranges of Exercise Price (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
RSUs
Ranges of Exercise Price [Line Items]
RSUs outstanding (in shares)	226,598
Options
Ranges of Exercise Price [Line Items]
Options exercisable (in shares)	997,977
Options exercisable weighted average remaining contractual life (years)	6 years 10 months 21 days
Options \| $0.82
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 0.82
Range of exercise price, maximum (in dollars per share)	$ 0.82
Options outstanding (in shares)	34,377
Options outstanding weighted average remaining contractual life (years)	4 years 11 days
Options exercisable (in shares)	34,377
Options exercisable weighted average remaining contractual life (years)	4 years 11 days
Options \| $1.32
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 1.32
Range of exercise price, maximum (in dollars per share)	$ 1.32
Options outstanding (in shares)	342,390
Options outstanding weighted average remaining contractual life (years)	5 years 5 months 12 days
Options exercisable (in shares)	338,145
Options exercisable weighted average remaining contractual life (years)	5 years 5 months 5 days
Options \| $1.48
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 1.48
Range of exercise price, maximum (in dollars per share)	$ 1.48
Options outstanding (in shares)	403,125
Options outstanding weighted average remaining contractual life (years)	7 years 11 days
Options exercisable (in shares)	281,243
Options exercisable weighted average remaining contractual life (years)	7 years 11 days
Options \| $6.80-$8.99
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 6.8
Range of exercise price, maximum (in dollars per share)	$ 8.99
Options outstanding (in shares)	761,211
Options outstanding weighted average remaining contractual life (years)	8 years 11 months 5 days
Options exercisable (in shares)	195,249
Options exercisable weighted average remaining contractual life (years)	8 years 10 months 10 days
Options \| $9.22-$10.98
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 9.22
Range of exercise price, maximum (in dollars per share)	$ 10.98
Options outstanding (in shares)	223,056
Options outstanding weighted average remaining contractual life (years)	9 years 4 months 6 days
Options exercisable (in shares)	6,273
Options exercisable weighted average remaining contractual life (years)	9 years 3 months 7 days
Options \| $19.62-$20.97
Ranges of Exercise Price [Line Items]
Range of exercise price- minimum (in dollars per share)	$ 19.62
Range of exercise price, maximum (in dollars per share)	$ 20.97
Options outstanding (in shares)	260,257
Options outstanding weighted average remaining contractual life (years)	7 years 11 months 23 days
Options exercisable (in shares)	142,690
Options exercisable weighted average remaining contractual life (years)	7 years 11 months 23 days
Options and RSUs
Ranges of Exercise Price [Line Items]
Options outstanding weighted average remaining contractual life (years)	7 years 9 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options and Equity Instruments Other than Options, Outstanding, Number	2,251,014	1,853,369

SHAREHOLDERS' EQUITY - Schedule of Options Issued to Consultants (Details) - Nonemployee Option - March 12, 2007	Dec. 31, 2016 $ / shares shares
Shareholders' equity (deficiency) [Line Items]
Options for shares of ordinary share (in shares)	3,454
Exercise price per share (in USD per shares) \| $ / shares	$ 0
Options exercisable (in shares)	3,454

SHAREHOLDERS' EQUITY - Options Issued to Consultants, Narrative (Details)	12 Months Ended
	Dec. 31, 2016 USD ($) national_insurance_policy	May 28, 2016
Share-based Goods and Nonemployee Services Transaction [Line Items]
Consultant fee as a percentage of the increase in market capitalization		10.00%
Measurement period of increase in market capitalization following achievement of milestone	10 days
Disclosure period following achievement of milestone	80 days
Number of national insurance policies required \| national_insurance_policy	5
Agreement term	12 months
One Active National Insurance Policy
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 6,000,000
Agreement term	18 months
Number of national insurance policies required to increase term \| national_insurance_policy	2
Two Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 5,000,000
Three Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Agreement term	24 months
Three, Four, or Five Active National Insurance Policies
Share-based Goods and Nonemployee Services Transaction [Line Items]
Payments due in cash or stock	$ 2,000,000

SHAREHOLDERS' EQUITY - Warrants to Purchase Ordinary Shares, Narrative (Details) - Ordinary Share	12 Months Ended
	Dec. 31, 2016 shares
Class of Warrant or Right [Line Items]
Number of warrants exercised (in shares)	138,702
Ordinary shares issued upon exercise of warrants (in shares)	45,116

SHAREHOLDERS' EQUITY - Schedule of Warrants to Purchase Ordinary Shares (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Dec. 28, 2016	Jan. 04, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 30, 2015
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)			3,008,316
Warrants exercisable (in shares)			3,008,316
Proceeds from long term loan			$ 20,000	$ 0	$ 0
Loan Agreement \| Term Loan
Class of Warrant or Right [Line Items]
Proceeds from long term loan	$ 8,000	$ 12,000
July 14, 2014
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)			403,804
Exercise price (in USD per share)			$ 10.08
Warrants exercisable (in shares)			403,804
December 30, 2015
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)						119,295
Exercise price (in USD per share)			$ 9.64
Warrants exercisable (in shares)			119,295
Minimum percentage in acquired company required to prevent warrants from becoming exercisable			50.00%
November 1, 2016
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)			2,437,500
Exercise price (in USD per share)			$ 4.75
Warrants exercisable (in shares)			2,437,500
December 28, 2016
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)	47,717
Exercise price (in USD per share)			$ 9.64
Warrants exercisable (in shares)			47,717
Number of warrants issued (in shares)	47,717

SHAREHOLDERS' EQUITY - Schedule of Non-cash Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 3,398	$ 2,345	$ 5,179
Cost of revenues
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	108	64	33
Research and development, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	559	425	4,364
Sales and marketing, net
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	811	571	275
General and administrative
Non-cash share-based compensation expense [Line Items]
Non-cash share-based compensation expense	$ 1,920	$ 1,285	$ 507

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development, net	$ 9,028	$ 5,937	$ 8,563
Collaborative Arrangement and License Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total payment obligation	6,300
Research and development, net	$ 1,700

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions			12 Months Ended
INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	Jan. 01, 2018	Jan. 04, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
INCOME TAXES [Line items]
Statutory tax rate (as a percent)		25.00%		25.00%	26.50%	26.50%
Beneficiary enterprise from productive activity, tax exemption period				10 years
Beneficiary enterprise from productive activity, maximum time from period of election for tax exemption				12 years
Carry-forward losses				$ 83.8
RRI
INCOME TAXES [Line items]
Statutory tax rate (as a percent)				40.00%	40.00%	40.00%
RRG
INCOME TAXES [Line items]
Statutory tax rate (as a percent)				30.00%	30.00%	30.00%
Minimum
INCOME TAXES [Line items]
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income				10.00%
Maximum
INCOME TAXES [Line items]
Beneficiary enterprise from productive activity, tax rate on dividend distributions from tax exempt income				25.00%
Scenario, Forecast \| Subsequent Event
INCOME TAXES [Line items]
Statutory tax rate (as a percent)	23.00%		24.00%

INCOME TAXES - Schedule of Profit (Loss) Before Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Domestic	$ (32,642)	$ (25,485)	$ (21,743)
Foreign	142	123	120
Profit (loss) before taxes	$ (32,500)	$ (25,362)	$ (21,623)

INCOME TAXES - Schedule of Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Current	$ 8	$ 114	$ 76
Deferred	(5)	(61)	(60)
Prior year taxes	0	0	29
Taxes on income	$ 3	$ 53	$ 45

INCOME TAXES - Schedule of Taxes on Income by Jurisdiction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Domestic	$ 0	$ 0	$ 0
Foreign	3	53	45
Taxes on income	$ 3	$ 53	$ 45

INCOME TAXES - Schedule of Deferred Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Carry forward tax losses	$ 20,938	$ 14,961
Research and development carry forward expenses-temporary differences	1,551	1,176
Accrual and reserves	223	206
Deferred tax assets before valuation allowance	22,712	16,343
Valuation allowance	(22,560)	(16,196)	$ (10,089)	$ (6,219)
Net deferred tax assets	$ 152	$ 147

INCOME TAXES - Net Changes in Total Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Valuation Allowance, Amount [Roll Forward]
Balance at beginning of year	$ (16,196)	$ (10,089)	$ (6,219)
Changes due to amendments to tax laws and exchange rate differences	917	0	0
Additions during the year	(7,281)	(6,107)	(3,870)
Balance at end of year	$ (22,560)	$ (16,196)	$ (10,089)

INCOME TAXES - Schedule of Reconciliation Between the Theoretical Tax Expense and the Actual Tax Expense (Benefit) (Details) - USD ($) $ in Thousands		12 Months Ended
	Jan. 04, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Loss before taxes, as reported in the consolidated statements of operations		$ (32,500)	$ (25,362)	$ (21,623)
Statutory tax rate	25.00%	25.00%	26.50%	26.50%
Theoretical tax benefits on the above amount at the Israeli statutory tax rate		$ (8,125)	$ (6,721)	$ (5,730)
Income tax at rate other than the Israeli statutory tax rate		10	16	12
Non-deductible expenses including equity based compensation expenses and other		857	651	1,864
Operating losses and other temporary differences for which valuation allowance was provided		7,281	6,107	3,870
Other		(20)	0	0
Taxes in respect of prior years		0	0	29
Taxes on income		$ 3	$ 53	$ 45

FINANCIAL EXPENSES, NET - Schedule of Financial Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ 85	$ 170	$ 200
Financial expenses related to loan agreement with Kreos	1,976	0	100
Bank commissions	34	36	36
Expenses (income) related to hedging transactions	(36)	(18)	61
Issuance of warrants to purchase convertible preferred share	0	0	835
Revaluation of fair value of warrants to purchase convertible preferred share	0	0	(776)
Issuance of convertible preferred shares	0	0	1,114
Issuance cost related to warrants liability	0	0	128
Financial expenses (income), net	$ 2,059	$ 188	$ 1,698

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Additional Information (Details)	12 Months Ended
	Dec. 31, 2016 segment
Segment Reporting [Abstract]
Number of reportable segments	1

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA - Schedule of Revenues and Long-Lived Assets by Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	$ 5,869	$ 3,746	$ 3,951
Long-lived assets	1,258	1,328
Israel
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	0	0	0
Long-lived assets	476	605
United States
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	3,741	2,439	2,186
Long-lived assets	565	483
Europe
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	1,144	820	1,254
Asia-Pacific
Summary of revenues and long-lived assets by geographic region [Line items]
Revenues	984	487	$ 511
Germany
Summary of revenues and long-lived assets by geographic region [Line items]
Long-lived assets	$ 217	$ 240

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA - Schedule of Major Customer Data as a Percentage of Total Revenues (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenue \| Customer Concentration \| Customer A
Major customer data as a percentage of total revenues [Line items]
Concentration risk (as a percent)	33.30%	14.80%	15.10%

SUBSEQUENT EVENTS - Additional Information (Details)	12 Months Ended
SUBSEQUENT EVENTS - Additional Information (Details)	Dec. 31, 2017
Maximum \| Scenario, Forecast \| Subsequent Event
Subsequent Event [Line Items]
Expected decrease in operating expenses	30.00%